Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study analyzing Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

Trial Profile

A study analyzing Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Olverembatinib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 May 2024 According to an Ascentage Pharma media release, the company announced that the results from this study has been selected for Poster Presentations and to be presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024).
  • 11 Jan 2024 New trial record
  • 12 Dec 2023 First Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top